Key Takeaways:
Black Diamond Therapeutics Inc.’s (Nasdaq: BDTX) silevertinib showed a 15.2-month median progression-free survival in a Phase 2 lung cancer trial, suggesting a potential new standard of care for a patient group with limited options and positioning the company for a pivotal study.
“The activity we are seeing with silevertinib across the full NCM spectrum, combined with its CNS activity, is highly encouraging,” said Dr. Julia Rotow, Clinical Director at the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, who will present the data at the upcoming American Society of Clinical Oncology (ASCO) meeting.
The trial enrolled 43 treatment-naive non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). As of an April 11 data cutoff, silevertinib achieved a 60% objective response rate (ORR) and a 91% disease control rate (DCR), according to the company. The safety profile was manageable, with the rate of Grade 3 or higher treatment-related adverse events dropping to 28% after a dose reduction.
The positive results de-risk the program and provide a clear path forward for Black Diamond, which saw its stock rise 20% ahead of the announcement. The company plans to meet with the U.S. Food and Drug Administration later in 2026 to finalize the design of a pivotal trial using a 150 mg once-daily dose.
Silevertinib is an investigational fourth-generation tyrosine kinase inhibitor (TKI) designed as a "MasterKey" therapy to target a wide range of EGFR mutations, including the NCMs that represent a meaningful and underserved subset of NSCLC patients. Historically, this group has seen poor progression-free survival with existing TKIs. The 15.2-month mPFS figure reported by Black Diamond significantly exceeds historical outcomes for currently available therapies in this population.
The drug's mechanism as a brain-penetrant inhibitor is a key differentiator. Progression via brain metastases is a frequent and devastating outcome for NSCLC patients. In the Phase 2 study, silevertinib demonstrated a CNS objective response rate of 86% in patients with existing brain lesions. Crucially, no patients in the trial developed new brain metastases, highlighting the drug's potential protective effect.
With a median follow-up of 11.2 months, 53% of patients remain on therapy, suggesting a durable response. The data from the study, which will be presented at ASCO on May 30, 2026, supports advancing a 150 mg once-daily dose into a pivotal trial.
Investors and analysts have responded positively to the data, which builds on previously announced preliminary results. Following the news, analysts at H.C. Wainwright raised their price target on BDTX to $11, while Freedom Capital Markets increased its target to $7. The company has stated it has a cash runway into the second half of 2028, providing sufficient capital to fund its next steps for silevertinib, including the initiation of a randomized Phase 2 trial in glioblastoma (GBM).
This article is for informational purposes only and does not constitute investment advice.
